Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Lilly's Portrazza available as first-line therapy for metastatic squamous NSCLC

Dec. 4, 2015

Phase II dose determined for tremelimumab plus gefitinib in EGFR-mutant NSCLC

Dec. 4, 2015

Anti-survivin vaccine induces immune response in phase II trial in DLBCL

Dec. 3, 2015

Dose expansion implemented in study of immunomodulator EF-022 in patients with solid tumors

Dec. 1, 2015

FDA issues complete response letter for Opdivo

Nov. 30, 2015

New CD137/HER2 bispecific Anticalin-based protein shows promising antitumoral activity

Nov. 30, 2015

New bispecific antibody prodrug shows preclinical efficacy

Nov. 27, 2015

Adaptimmune initiates phase I/II study of NY-ESO TCR therapy in NSCLC

Nov. 27, 2015

Aduro's CRS-207 receives EMA orphan drug designation for malignant pleural mesothelioma

Nov. 27, 2015

Combination of pembrolizumab and chemotherapy feasible in metastatic cancer

Nov. 26, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...